SCHEMBL15614697

SCHEMBL15614697

Cc1cccc(Nc2nc3nonc3nc2N2CCOCC2)c1C

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.84
ALDH1A1 P00352 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
SMN1; SMN2 Q16637 5/20 0.56
TP53 P04637 5/20 0.56
MAPT P10636 5/20 0.56
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
PIK3CD O00329 1/20 0.48
PIK3C2B O00750 1/20 0.48
MTOR P42345 1/20 0.48
PIK3CG P48736 1/20 0.48
CDKN1A P38936 1/20 0.47
RAB9A P51151 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HPGD P15428 1/20 0.43
GAA P10253 3/20 0.43
CCNK O75909 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16941526 0.89 LMNA (0.67) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3051668 0.82 LMNA (0.74) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3050959 0.76 ALDH1A1 (0.67) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL15614740 0.73 MAPT (0.74) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL15614741 0.73 SMN1; SMN2 (0.67) LMNASMN1; SMN2TP53MAPTKMT2A
SCHEMBL3048490 0.72 LMNA (0.60) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3061283 0.71 LMNA (0.58) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL20570269 0.70 TP53 (0.67) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3049996 0.70 CYP1A2 (0.69) LMNAALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL15614742 0.70 SMN1; SMN2 (0.59) LMNAALDH1A1SMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150210717-A1 SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) 2015-07-30 US disclosed
WO-2014041125-A1 SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS BADEN-WÜRTTEMBERG STIFTUNG GMBH (DE) 2014-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210717-A1 SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS CDKN1A, ING2, BCCIP LMNA 2489/4885ALDH1A1 1754/4885CYP1A2 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.